Department of Computer Science and Engineering, University of California, San Diego, California 92093, USA; email:
Department of Pediatrics, University of California, San Diego, California 92093, USA.
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:253-270. doi: 10.1146/annurev-pharmtox-042017-031849. Epub 2017 Oct 2.
The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy.
人类微生物组蕴藏着巨大的遗传和生化多样性来源,其对治疗反应的影响才刚刚开始被理解。这种更深入的认识非常重要,因为与人类基因组相比,人类微生物组在不同个体之间的差异要大得多,而且也更容易改变。在这里,我们描述了一些导致个体和人群之间人类微生物组差异的主要因素。然后,我们描述了肠道微生物如何修饰特定化疗药物(包括非甾体抗炎药和强心苷)作用的许多方式,并概述了粪便微生物移植作为一种治疗方法的潜力。有趣的是,微生物还通过在远处作用的各种途径改变宿主对治疗药物的反应。最后,我们讨论了围绕使用微生物组对药物反应进行个体分层的一些计算和实际问题,我们设想未来将对微生物组进行修饰,以提高每个人从治疗中获益的潜力。